Omegaven (w-3 Fish Oil) Supplemented Parenteral Nutrition in Subjects of SICU.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT00172198

Recruitment Status : Unknown

Verified January 2005 by National Taiwan University Hospital.
Recruitment status was: Recruiting

First Posted : September 15, 2005

Last Update Posted : September 15, 2005

Sponsor:

Information provided by:

National Taiwan University Hospital

Study Description

Brief Summary:

A prospective, controlled, randomized, study evaluating the clinical efficacy, including nutritional status, immune function and safety of Omegaven (ω-3 fish oil) supplemented parenteral nutrition in subjects of SICU.
Study patients are the critical ill patients in SICU of NTUH and the enrolled patients will be 30 subjects ,including 15 in each treatment group.
During parenteral nutrition, fat emulsions will be given separately from amino acid and glucose solutions. Infusion pump must be used.The recommended infusion duration of the daily lipid emulsion is 16 hours (0.0625 g fat/kg B.W./hour) from 8:00 am to 12:00 pm.
During the study the assessments of safety and efficacy are to be performed according to case report form. The assessment for safety variables including blood pressure、heat rate 、body temperature、liver function、renal function、coagulation、WBC、lipid profile etc. In addition，the assessments for efficacy variables including lymphocytes、cytokines(IL-1、IL-2、IL-6、IL-8、IL-11、IL-18、OX40 ligand、G-CSF、FN-γ、TGF-β1、TNF-α etc)、incidence of infections、 length of ICU and hospital stay、mortality etc.

Condition or disease	Intervention/treatment	Phase
Critical Ill Patients in SICU	Drug: Omegaven 10%	Phase 4

Detailed Description:

A prospective, controlled, randomized, study evaluating the clinical efficacy, including nutritional status, immune function and safety of Omegaven (ω-3 fish oil) supplemented parenteral nutrition in subjects of SICU.
Study patients are the critical ill patients in SICU of NTUH and the enrolled patients will be 30 subjects ,including 15 in each treatment group.
During parenteral nutrition, fat emulsions will be given separately from amino acid and glucose solutions. Infusion pump must be used.The recommended infusion duration of the daily lipid emulsion is 16 hours (0.0625 g fat/kg B.W./hour) from 8:00 am to 12:00 pm.
During the study the assessments of safety and efficacy are to be performed according to case report form. The assessment for safety variables including blood pressure、heat rate 、body temperature、liver function、renal function、coagulation、WBC、lipid profile etc. In addition，the assessments for efficacy variables including lymphocytes、cytokines(IL-1、IL-2、IL-6、IL-8、IL-11、IL-18、OX40 ligand、G-CSF、FN-γ、TGF-β1、TNF-α etc)、incidence of infections、 length of ICU and hospital stay、mortality etc.

Study Design

Layout table for study information

Study Type :	Interventional (Clinical Trial)
Enrollment :	30 participants
Allocation:	Randomized
Intervention Model:	Parallel Assignment
Masking:	Double
Primary Purpose:	Treatment
Official Title:	A Prospective, Controlled, Randomized, Study Evaluating the Clinical Efficacy, Including Nutritional Status, Immune Function and Safety of Omegaven (w-3 Fish Oil) Supplemented Parenteral Nutrition in Subjects of SICU.
Study Start Date :	March 2005
Study Completion Date :	March 2007

Resource links provided by the National Library of Medicine

Drug Information available for: Fish oil

U.S. FDA Resources

Arms and Interventions

Outcome Measures

Primary Outcome Measures :

Lymphocytes:T4,T8,B,T,NK
Cytokine secretion:IL-1、IL-2、IL-6、IL-8、IL-11、IL-18、OX40 ligand、G-CSF、FN-γ、TGF-β1、TNF-α.
Clinical outcome:incidence of infections,length of ICU and hospital stay,ventilation,mortality

Secondary Outcome Measures :

Liver function(AST,ALT,bilirubin,ALP,rGT,albumin)
renal function(BUN,creatinine)
AC blood sugar
coagulation(INR,aPTT)
sodium
potassium
chloride
calcium
magnesium
phosphate
total white blood cell counts
platelets
haemoglobin
haematoc

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information

Ages Eligible for Study:	15 Years to 75 Years (Child, Adult, Older Adult)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Male and female patients between 15 and 75 years of age
Expected ICU stay and TPN support requirement > 7 days
Hemodynamically stable
Serum bilirubin < 2.5 mg/dl
Serum creatinine < 1.4 mg/dl
INR (international Normalized ratio of PT) < 1.4
Written informed consent from the subject

Exclusion Criteria:

Pregnant or lactating women. (Pre-menopause women, capable of bearing children will undergo pregnancy test)
General contraindications of infusion therapy; acute pulmonary oedema,hyperhydration and decompensated cardiac insufficiency
Known hypersensitivity to egg- or soy protein or any of the ingredients
Severe blood coagulation disorders
Shock necessitating acute resuscitation at the discretion of the investigator
Diabetes mellitus with known ketoacidosis within 7 days of onset of study treatment
APACHE II score > 25
Renal insufficiency defined as serum creatinine value of >1.4 mg/dl
Subjects with severe liver dysfunction which contraindicates the use of parenteral nutrition at the discretion of the investigator
Known type IV hyperlipidemia, disturbances in lipid metabolism or hypertriglyceridemia (at the time of inclusion, a blood sample (fasting) for serum triglyceride assessment has to be taken. The sample has to be analysed before start of trial treatment. In case of fasting serum triglyceride value of >4 mmol/l (>354 mg/dl) the subject must be withdrawn.
Unconscious or uncooperative patients
Participation in a clinical study with an investigational drug or an investigational medical device within one month prior to start of study

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00172198

Contacts

Layout table for location contacts

Contact: Hong-Shiee Lai, MD, PhD	886-2-23123456 ext 5112	hslai@ha.mc.ntu.edu.tw

Locations

Layout table for location information

Taiwan
National Taiwan University Hospital	Recruiting
Taipei, Taiwan, 100
Contact: Hong-Shiee Lai, M.D., Ph.D. 886-2-23123456 ext 5112 hslai@ha.mc.ntu.edu.tw

Sponsors and Collaborators

National Taiwan University Hospital

Investigators

Layout table for investigator information

Principal Investigator:	Hong-Shiee Lai, Professor	National Taiwan University Hospital, Taipei, Taiwan

More Information

Publications:

Roulet M, Frascarolo P, Pilet M, Chapuis G. Effects of intravenously infused fish oil on platelet fatty acid phospholipid composition and on platelet function in postoperative trauma. JPEN J Parenter Enteral Nutr. 1997 Sep-Oct;21(5):296-301.

Layout table for additonal information

ClinicalTrials.gov Identifier:	NCT00172198
Other Study ID Numbers:	183CL1
First Posted:	September 15, 2005 Key Record Dates
Last Update Posted:	September 15, 2005
Last Verified:	January 2005

Keywords provided by National Taiwan University Hospital:


w-3 fish oil Nutrition immune intensive care patients

To Top